euro adhoc: Intercell AG / quarterly or semiannual financial statement / Intercell AG announces Q3 results and presents business update: All development programs on track - Profitability expected for

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

quaterly report

19.11.2007

Vienna (Austria), November 19, 2007 - Today, vaccine company
Intercell AG (VSE: ICLL) announced its financial results for the
third quarter 2007, and presented an update on the Company´s
development programs.

All development programs fully on track

Japanese Encephalitis:

» Significant progress for leading prophylactic vaccine program on
track for market approvals - Finalization of EMEA-MAA and US-BLA
filing planned for December 2007

» Results of Phase II for the vaccine in children expected in early
2008

Hospital acquired infections:

» S. aureus vaccine - Start of clinical Phase II trial (with Merck &
Co., Inc.) expected within the next weeks

» Pseudomonas vaccine - preparations for start of clinical Phase
II/III trials in 2008 on track

Hepatitis C:

» Statistically significant viral load reduction and good safety
profile for therapeutic vaccine in interim analysis - full study
data expected for Q1 2008

» Further clinical program under co-development arrangement with
Novartis likely to include IC31®

IC31® & AIP®:

» IC31® - Influenza vaccine: All individuals within Phase I study
vaccinated - results expected for early 2008

» IC31® - Tuberculosis vaccine: Two further clinical trials with the
Danish Statens Serum Institut (SSI) expected to start this year

» Pneumococcus vaccine: Preparations for start of Phase I study in
2008 for novel protein-based vaccine on track

Novartis alliance:

» Transaction closed as announced in July - Total upfront
contribution of EUR 270 m - Significant further milestones expected
- 4.8 m shares issued to Novartis at a price of EUR 31.25 per share
in September

» Full implementation for improved Influenza vaccine and
co-development in Hepatitis C started in Q4 2007

Strong financial position - Profitability expected for full year 2007

» EUR 6.5 m net loss for Q3 2007 compared to EUR 9.5 m in Q3 2006.
This means a decrease of 31.2 percent

» Increase of aggregate revenues - EUR 7.4 m in Q3 2007 compared to
EUR 0.7 m in Q3 2006

» EUR 9.8 m R&D expenses in Q3 2007 - up 17.0 percent compared to Q3
2006 following progress of development programs

» Strong cash position with EUR 218.6 m in liquid funds at September
30, 2007.Given already committed further payments, cash position at
the end of 2007 expected to be approx. EUR 300 m

» Full year 2007 expected to be profitable based on already confirmed
licensing income. Growth in profitability expected for 2008

Management Board:

» Management Board, with Gerd Zettlmeissl as Chief Executive Officer,
Werner Lanthaler as Chief Financial Officer, and Alexander von
Gabain as Chief Scientific Officer, appointed for a further
three-year term. Thomas Lingelbach appointed as a new member of the
Management Board as Chief Operating Officer

end of announcement euro adhoc 19.11.2007 07:24:55
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market